We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-12.52%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.5B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
1.63%
Top 10 Hldgs %
41.52%
Holding
149
New
17
Increased
43
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$108M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$75.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$71.1M
4
LLY icon
Eli Lilly
LLY
+$70.2M
5
UNH icon
UnitedHealth
UNH
+$67.9M

Top Sells

Rank Stock Value
1
HNT
HEALTH NET INC
HNT
+$205M
2
VTRS icon
Viatris
VTRS
+$149M
3
AFFX
Affymetrix Inc
AFFX
+$75.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$59.4M
5
BMY icon
Bristol-Myers Squibb
BMY
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.92%
2 Financials 0.22%
3 Technology 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
101
Enanta Pharmaceuticals
ENTA
$362M
$7.33M 0.08%
249,400
-254,900
-51% -$7.1M
BITI
102
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$7.09M 0.07%
268,672
– –
ASMB icon
103
Assembly Biosciences
ASMB
$497M
$7.01M 0.07%
116,425
– –
RDHL
104
Redhill Biopharma
RDHL
$4.26M
$6.92M 0.07%
565
– –
SGYP
105
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$6.28M 0.07%
2,276,648
– –
MGNX icon
106
MacroGenics
MGNX
$234M
$5.94M 0.06%
317,000
– –
ADXS
107
DELISTED
Advaxis Inc
ADXS
$5.75M 0.06%
42,440
– –
QGENF
108
DELISTED
QIAGEN NV
QGENF
$5.74M 0.06%
+256,800
New +$5.74M
IOVA icon
109
Iovance Biotherapeutics
IOVA
$2.02B
$5.19M 0.05%
1,022,100
– –
MRNS
110
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.19M 0.05%
241,250
– –
BHC icon
111
Bausch Health
BHC
$1.7B
$5.13M 0.05%
194,900
-195,100
-50% -$14.4M
NVTA
112
DELISTED
Invitae Corporation
NVTA
$4.67M 0.05%
456,666
– –
CNXR
113
DELISTED
Connecture, Inc.
CNXR
$4.45M 0.05%
1,740,000
– –
MCRB icon
114
Seres Therapeutics
MCRB
$45.9M
$4.43M 0.05%
8,332
– –
MRTX
115
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.23M 0.04%
197,859
+165,659
+514% +$3.7M
ASND icon
116
Ascendis Pharma A/S
ASND
$16.6B
$4.12M 0.04%
222,223
– –
ADAP
117
DELISTED
Adaptimmune Therapeutics
ADAP
$3.57M 0.04%
438,784
– –
CERS icon
118
Cerus
CERS
$577M
$3.43M 0.04%
578,300
-5,926,100
-91% -$32.8M
VTRS icon
119
Viatris
VTRS
$20.8B
$3.23M 0.03%
69,800
-3,087,200
-98% -$149M
ANAC
120
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$2.85M 0.03%
53,300
– –
ALIM
121
DELISTED
Alimera Sciences
ALIM
$2.63M 0.03%
100,000
– –
ROKA
122
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$2.22M 0.02%
322,043
– –
QURE icon
123
uniQure
QURE
$2.74B
$2.19M 0.02%
+184,800
New +$2.73M
PTLA
124
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.04M 0.02%
+100,000
New +$3.17M
XYLO
125
DELISTED
Xylo Technologies
XYLO
$1.61M 0.02%
375
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2016 Portfolio in Review

As of Q1 2016, OrbiMed held 149 positions worth $9.5B, down 14% from $11B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q1 2016 filing shows 17 new, 43 increased, 27 reduced and 8 closed positions. Its largest new stake was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M. The largest sale was HEALTH NET INC, an estimated $205M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q1 2016 buy was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M.
  • OrbiMed added most to Vertex Pharmaceuticals in Q1 2016, an estimated $108M increase.
  • OrbiMed's biggest Q1 2016 reduction was Viatris, cutting an estimated $149M.
  • OrbiMed fully exited HEALTH NET INC in Q1 2016, selling an estimated $205M.
  • OrbiMed's ten largest holdings make up 42% of its $9.5B portfolio in Q1 2016.
  • OrbiMed opened 17 new positions and closed 8 in Q1 2016.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $9.5B.

Based on OrbiMed's 13F filing for Q1 2016, filed 16 May 2016.